PRIME, PRIME 2 Data Show 12-, 24-Week Improvements in Patients With Prurigo Nodularis

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.

Related Keywords

,Worst Itch Numeric Rating Scale ,Investigator Global Assessment ,Dermatology Life Quality Index ,Prurigo Nodularis ,Dupilumab ,Wi Nrs ,Iga Pn S ,